{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:23:56Z","timestamp":1741667036999,"version":"3.38.0"},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"DOI":"10.12788\/cutis.1166","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:40:28Z","timestamp":1741624828000},"source":"Crossref","is-referenced-by-count":0,"title":["Apremilast Treatment Outcomes and Adverse Events in Psoriasis Patients With HIV"],"prefix":"10.12788","volume":"115","author":[{"given":"Kyle C.","family":"Lauck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","container-title":["Cutis"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/issues\/articles\/CT115002066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:40:29Z","timestamp":1741624829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/dermatology\/article\/272244\/apremilast-treatment-outcomes-and-adverse-events-psoriasis-patients-hiv"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,1]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.12788\/cutis.1166","relation":{},"subject":[],"published":{"date-parts":[[2025,2,1]]}}}